Literature DB >> 35983422

Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary.

John Anderson1, James R Gavin2, Davida F Kruger3, Eden Miller4.   

Abstract

Entities:  

Year:  2022        PMID： 35983422      PMCID： PMC9331622          DOI： 10.2337/cd22-0020

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  26 in total

1.  Pancreatic safety of incretin-based drugs--FDA and EMA assessment.

Authors:  Amy G Egan; Eberhard Blind; Kristina Dunder; Pieter A de Graeff; B Timothy Hummer; Todd Bourcier; Curtis Rosebraugh
Journal:  N Engl J Med       Date:  2014-02-27       Impact factor: 91.245

2.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY.

Authors:  Alan J Garber; Yehuda Handelsman; George Grunberger; Daniel Einhorn; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Michael A Bush; Ralph A DeFronzo; Jeffrey R Garber; W Timothy Garvey; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Leigh Perreault; Paul D Rosenblit; Susan Samson; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2020-01       Impact factor: 3.443

3.  Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.

Authors:  Lotte Bjerre Knudsen; Lars Wichmann Madsen; Søren Andersen; Kasper Almholt; Anne S de Boer; Daniel J Drucker; Carsten Gotfredsen; Frederikke Lihme Egerod; Anne Charlotte Hegelund; Helene Jacobsen; Søren Dyring Jacobsen; Alan C Moses; Anne-Marie Mølck; Henriette S Nielsen; Jette Nowak; Helene Solberg; Tu D L Thi; Milan Zdravkovic; Ulrik Moerch
Journal:  Endocrinology       Date:  2010-03-04       Impact factor: 4.736

Review 4.  GLP-1 receptor agonists: a review of head-to-head clinical studies.

Authors:  Jennifer M Trujillo; Wesley Nuffer; Samuel L Ellis
Journal:  Ther Adv Endocrinol Metab       Date:  2015-02       Impact factor: 3.565

5.  4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Medical Care in Diabetes-2022.

Authors:  Boris Draznin; Vanita R Aroda; George Bakris; Gretchen Benson; Florence M Brown; RaShaye Freeman; Jennifer Green; Elbert Huang; Diana Isaacs; Scott Kahan; Jose Leon; Sarah K Lyons; Anne L Peters; Priya Prahalad; Jane E B Reusch; Deborah Young-Hyman
Journal:  Diabetes Care       Date:  2022-01-01       Impact factor: 19.112

6.  10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022.

Authors: 
Journal:  Diabetes Care       Date:  2022-01-01       Impact factor: 17.152

7.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Authors:  Marc A Pfeffer; Brian Claggett; Rafael Diaz; Kenneth Dickstein; Hertzel C Gerstein; Lars V Køber; Francesca C Lawson; Lin Ping; Xiaodan Wei; Eldrin F Lewis; Aldo P Maggioni; John J V McMurray; Jeffrey L Probstfield; Matthew C Riddle; Scott D Solomon; Jean-Claude Tardif
Journal:  N Engl J Med       Date:  2015-12-03       Impact factor: 91.245

8.  2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee.

Authors:  Sandeep R Das; Brendan M Everett; Kim K Birtcher; Jenifer M Brown; James L Januzzi; Rita R Kalyani; Mikhail Kosiborod; Melissa Magwire; Pamela B Morris; Joshua J Neumiller; Laurence S Sperling
Journal:  J Am Coll Cardiol       Date:  2020-08-05       Impact factor: 24.094

9.  Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes.

Authors:  Hertzel C Gerstein; Naveed Sattar; Julio Rosenstock; Chinthanie Ramasundarahettige; Richard Pratley; Renato D Lopes; Carolyn S P Lam; Nardev S Khurmi; Laura Heenan; Stefano Del Prato; Leanne Dyal; Kelley Branch
Journal:  N Engl J Med       Date:  2021-06-28       Impact factor: 91.245

10.  Medullary Thyroid Carcinoma Surveillance Study: A Case-Series Registry.

Authors:  Paula M Hale; Ayad K Ali; John B Buse; Mary Kate McCullen; Douglas S Ross; Mary Elizabeth Sabol; R Michael Tuttle; Annette Stemhagen
Journal:  Thyroid       Date:  2020-07-09       Impact factor: 6.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.